$174 Million is the total value of Samsara BioCapital, LLC's 28 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRNB | Buy | Principia Biopharma Inc | $23,814,000 | +41.7% | 401,046 | +30.7% | 13.70% | +70.2% |
| ALLK | Buy | Allakos Inc | $12,055,000 | -47.9% | 270,965 | +11.7% | 6.94% | -37.4% |
| BCEL | Buy | Atreca Inc | $9,878,000 | +8.0% | 596,838 | +0.9% | 5.68% | +29.7% |
| LQDA | Buy | Liquidia Technologies Inc | $4,775,000 | +16.5% | 1,013,773 | +5.8% | 2.75% | +40.0% |
| RYTM | New | Rhythm Pharmaceuticals Inc | $4,205,000 | – | 276,289 | +100.0% | 2.42% | – |
| MLND | Buy | Millendo Therapeutics Inc | $3,967,000 | -17.7% | 751,301 | +5.0% | 2.28% | -1.1% |
| PIRS | Buy | Pieris Pharmaceuticals Inc | $3,694,000 | +44.9% | 1,620,249 | +130.1% | 2.13% | +74.1% |
| AIMT | New | Aimmune Therapeutics, Inc. | $3,354,000 | – | 232,571 | +100.0% | 1.93% | – |
| ISEE | Buy | Iveric Bio, Inc. | $2,967,000 | -50.6% | 862,552 | +23.2% | 1.71% | -40.7% |
| ACRS | New | Aclaris Therapeutics, Inc. | $2,712,000 | – | 2,608,117 | +100.0% | 1.56% | – |
| RCKT | New | Rocket Pharmaceuticals Inc | $1,788,000 | – | 128,197 | +100.0% | 1.03% | – |
| KALV | Buy | KalVista Pharmaceuticals Inc | $1,287,000 | -39.0% | 168,174 | +41.9% | 0.74% | -26.7% |
| PTLA | New | Portola Pharmaceuticals Inc | $1,139,000 | – | 159,772 | +100.0% | 0.66% | – |
| BLUE | New | Bluebird Bio Inc | $1,139,000 | – | 24,790 | +100.0% | 0.66% | – |
| AKRO | New | Akero Therapeutics, Inc. | $1,060,000 | – | 50,000 | +100.0% | 0.61% | – |
| AMRN | New | Amarin Corp PLCspons adr new | $781,000 | – | 195,195 | +100.0% | 0.45% | – |
| KALA | New | Kala Pharmaceuticals Inc | $563,000 | – | 64,102 | +100.0% | 0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.